Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Page 1
Characteristics of the Reminder that Triggers Object Recognition Memory Reconsolidation in Mice.
Ameneiro L, Zalcman G, Robles A, Romano A. Ameneiro L, et al. Among authors: zalcman g. Neuroscience. 2022 Aug 10;497:206-214. doi: 10.1016/j.neuroscience.2022.03.014. Epub 2022 Mar 18. Neuroscience. 2022. PMID: 35314253
Memory reconsolidation can be evidenced by delivering either an amnesic agent or a memory enhancer after reactivation and testing the resulting long-term memory alteration. Here we trained male mice for 15 min to induce a strong memory formation. ...
Memory reconsolidation can be evidenced by delivering either an amnesic agent or a memory enhancer after reactivation and testing the result …
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F; French Cooperative Thoracic Intergroup (IFCT). Trédaniel J, et al. Among authors: zalcman g. Cancer Radiother. 2022 Sep;26(5):670-677. doi: 10.1016/j.canrad.2021.12.005. Epub 2022 Mar 5. Cancer Radiother. 2022. PMID: 35260342 Free article. Clinical Trial.
Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long-term prognosis. This phase II trial (IFCT-0803) sought to evaluate whether adding cetuximab to cisplatin and pemetrexed chemoradiothera …
Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long- …
Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial.
Guisier F, Deslee G, Birembaut P, Escarguel B, Chapel F, Bota S, Métayer J, Lachkar S, Capron F, Homasson JP, Taulelle M, Quintana M, Raspaud C, Messelet D, Benzaquen J, Hofman P, Baddredine J, Paris C, Cales V, Laurent P, Vignaud JM, Ménard O, Copin MC, Ramon P, Bouchindhomme B, Tavernier JY, Quintin I, Quiot JJ, Galateau-Sallé F, Zalcman G, Piton N, Thiberville L. Guisier F, et al. Among authors: zalcman g. Eur Respir J. 2022 Sep 15;60(3):2101946. doi: 10.1183/13993003.01946-2021. Print 2022 Sep. Eur Respir J. 2022. PMID: 35236723 Free article. Clinical Trial.
After baseline lung computed tomography (CT) and autofluorescence bronchoscopy (AFB) to exclude lung cancer and bronchial severe squamous dysplasia or carcinoma in situ (CIS), patients were assigned to standard surveillance (arm A) with CT and AFB at 36 months or to intensive sur …
After baseline lung computed tomography (CT) and autofluorescence bronchoscopy (AFB) to exclude lung cancer and bronchial severe squamous dy …
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. Peters S, et al. Among authors: zalcman g. Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3. Ann Oncol. 2022. PMID: 35124183 Free article. Clinical Trial.
CONCLUSIONS: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology....
CONCLUSIONS: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemothe …
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment.
Gounant V, Brosseau S, Zalcman G. Gounant V, et al. Among authors: zalcman g. Ther Adv Med Oncol. 2021 Dec 10;13:17588359211061956. doi: 10.1177/17588359211061956. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34917175 Free PMC article. Review.
In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term results. For about 15 years, first-line chemotherapy has been primarily based on a doublet of pemetrexed and cisplatin. ...
In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term …
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G. Gounant V, et al. Among authors: zalcman g. J Thorac Oncol. 2022 Feb;17(2):239-251. doi: 10.1016/j.jtho.2021.10.015. Epub 2021 Nov 16. J Thorac Oncol. 2022. PMID: 34798306 Free PMC article.
Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p …
Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (& …
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano JP, Helissey C, Chouaid C, Molinier O, Dhalluin X, Doucet L, Hureaux J, Cazes A, Zalcman G. Gounant V, et al. Among authors: zalcman g. Cancers (Basel). 2021 Mar 2;13(5):1040. doi: 10.3390/cancers13051040. Cancers (Basel). 2021. PMID: 33801285 Free PMC article.
Certain patients with very poor general condition could derive long-term benefit from nivolumab salvage therapy....
Certain patients with very poor general condition could derive long-term benefit from nivolumab salvage therapy....
In vitro bone metastasis dwelling in a 3D bioengineered niche.
Han W, El Botty R, Montaudon E, Malaquin L, Deschaseaux F, Espagnolle N, Marangoni E, Cottu P, Zalcman G, Parrini MC, Assayag F, Sensebe L, Silberzan P, Vincent-Salomon A, Dutertre G, Roman-Roman S, Descroix S, Camonis J. Han W, et al. Among authors: zalcman g. Biomaterials. 2021 Feb;269:120624. doi: 10.1016/j.biomaterials.2020.120624. Epub 2020 Dec 24. Biomaterials. 2021. PMID: 33421710
In particular, patient-derived xenografts being considered as a better approach than cell lines to achieve clinically relevant results, we demonstrate the ability of this biomimetic bone niche model to host patient-derived xenografted metastatic breast cancer cells. These patient …
In particular, patient-derived xenografts being considered as a better approach than cell lines to achieve clinically relevant results, we d …
Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
Bouchez C, Pluvy J, Soussi G, Nguenang M, Brosseau S, Tourne M, Collin M, Théou-Anton N, Guyard A, Ammar J, Khalil A, Zalcman G, Gounant V. Bouchez C, et al. Among authors: zalcman g. BMC Cancer. 2020 Dec 3;20(1):1186. doi: 10.1186/s12885-020-07630-6. BMC Cancer. 2020. PMID: 33272243 Free PMC article.
CaMKII Isoforms in Learning and Memory: Localization and Function.
Zalcman G, Federman N, Romano A. Zalcman G, et al. Front Mol Neurosci. 2018 Dec 4;11:445. doi: 10.3389/fnmol.2018.00445. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30564099 Free PMC article. Review.
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a key protein kinase in neural plasticity and memory, as have been shown in several studies since the first evidence in long-term potentiation (LTP) 30 years ago. However, most of the studies were focused mainly in …
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a key protein kinase in neural plasticity and memory, as have been shown in sever …
21 results